Learn, Analyse & Invest
only with
only with
+91
Download Orca
Welcure Drugs & Pharmaceuticals Ltd.
Welcure Drugs&Pharma
₹ 0.00
0.00 (0.00)%
NSE
BSE
Trading
Small-cap - With a market cap of ₹34.61 Cr.
| EX-Date | Purpose |
|---|---|
| 26 04 2021 | Audited Results |
| 12 07 2021 | Quarterly Results |
| 25 10 2021 | Quarterly Results |
| 22 01 2022 | Quarterly Results |
| 15 04 2022 | Audited Results |
| 16 07 2022 | Quarterly Results |
| 08 10 2022 | Quarterly Results |
| 29 11 2022 | Preferential Issue of shares & Increase in Authorised Capital Inter alia, to transact the following matters: 1. To discuss and consider a proposal for raising funds by issue of equity shares/warrants/any other equity linked securities, through preferential basis, subject to such approvals, as may be required under applicable laws. 2. To consider the increase in authorised share capital of the company. 3. To consider the name change of the company. 4. To consider the change in object clause of the company. 5. To consider reclassification of promoters. 6. Any other Business as may be considered necessary. |
| 13 02 2023 | Quarterly Results |
| 14 02 2023 | Quarterly Results (Revised) |
| 29 05 2023 | Quarterly Results & Audited Results |
| 11 07 2023 | Quarterly Results & Audited Results |
| 14 08 2023 | Quarterly Results |
| 14 11 2023 | Quarterly Results |
| 14 02 2024 | Quarterly Results |
| 28 03 2024 | Inter alia, to consider and approve:- (1) To Consider and Approve the Resignation of M/s BMGS &Associates Accountant of the Company. (2) To consider the Appointment of M/s Gupta Rustagi& Co., Chartered Accountant, as the statutory auditor of the company. (3) To Consider and Approve the Resignation of Priti Rajesh Kharwar Additional Non Executive Director (4) To consider the Appointment of Mr. Ashish Abbi as a Non-executive Independent director of the company. |
| 21 10 2024 | Inter alia, to Consider Forfeiture of Partly Paid-up Equity Shares. The Board noted that the holders of 1,53,900 partly paid up shares have failed to pay the balance money/allotment money. |
| 13 11 2024 | Quarterly Results |
| 14 11 2024 | Quarterly Results (Revised) |
| 14 02 2025 | Quarterly Results |
| 14 05 2025 | Inter alia, to consider and approve:- 1. To consider the appointment of Mr. Chintan Didawala Ganpat (DIN: 11088268) as Managing Director of the Company. 2. To consider the Alteration in Main Objects Clause of Memorandum of Association of the Company by addition of New Objects. 3. To consider the Increase in the Authorized Share Capital of the Company and consequent amendment in Memorandum of the Company, if any; 4. Conduct Postal Ballot by means of E-voting for obtaining approval of the members of the Company |
| 29 05 2025 | Audited Results |
| 05 08 2025 | Quarterly Results & Inter alia, to consider and approve:- 1. To change the Corporate Office of the Company. 2. To appoint Mr. Ravi Thakor (DIN 11210729) as an Additional Non- Executive Non- Independent Director of the Company. 3. To appoint Mr. Yogeshkumar Prajapati (DIN 11210767) as an Additional Non- Executive Independent Director of the Company. 4. To appoint Mrs. Bhumika Pradhan (DIN 10167275) as an Additional Non- Executive Independent Director of the Company. 5. To consider any other matter, with the permission of the Chair. |
| 22 08 2025 | Stock Split & Bonus issue |
| 28 08 2025 | Inter alia, to consider and approve:- (1) Proposed Agro-Pharma Research Laboratory and (2) to consider fund-raising by QIP |
| 02 09 2025 | A.G.M. |
| 25 09 2025 | Board Meeting Postponed (Cancelled) |
| 27 09 2025 | Inter alia, to consider and approve:- (1) To take on record and deliberate upon the Letter of Intent (LOI) received from Telexcell Trade PTE LTD, Singapore, for a proposed acquisition of up to 25% equity stake in Welcure Drugs & Pharmaceuticals Ltd. at an indicative price of Rs.20 per share (a substantial premium over the prevailing market price). 2. To initiate the process of comprehensive due diligence in respect of the proposed transaction, including legal, financial, and regulatory aspects. 3. To consider authorizing the Company s representatives to negotiate and finalize the terms of definitive agreements, in alignment with Welcure s long-term growth strategy and compliance with applicable regulatory frameworks. 4. To explore enabling mechanisms for shareholder approval through postal ballot / general meeting, in line with SEBI, RBI, FEMA, and stock exchange requirements. 5. To deliberate on future strategic growth opportunities in global pharmaceutical and chemical exports, leveraging Telexcell s global trade networktd. at an indicative price of Rs. 20 per share (a substantial premium over the prevailing market price). |
| 13 11 2025 | Quarterly Results |
| 27 11 2025 | Inter-alia, to transact the following businesses:- 1. To augment the financial resources of the Company via funds raising by way of issue of equity shares/convertible instruments/other securities through preferential allotment, right issue, QIP?s, ADR GDR, FCCB or any other method or combination thereof, in one or more trenches; 2. To consider any other matter, with the permission of the Chair; |
| 01 12 2025 | Inter-alia, to transact the following businesses:- 1. To augment the financial resources of the Company via funds raising by way of issue of equity shares/convertible instruments/other securities through preferential allotment, right issue, QIP?s, ADR GDR, FCCB or any other method or combination thereof, in one or more trenches; 2. To consider any other matter, with the permission of the Chair; |
| 05 12 2025 | Right Issue of Equity Shares |
| 12 02 2026 | Quarterly Results |
News
